Evanston, IL's Naurex nailed down another $25 million in venture funding to accelerate its two-pronged depression program, posting positive midstage results for its top prospect.
Paris-based Enterome Bioscience, focused on the gut microbiome, has raised €10 million ($11.5 million) in the first tranche of its Series B fundraising. Seventure (including from its new Health for Life Capital fund), Lundbeckfond Ventures and Omnes Capital contributed cash to the deal.
Lightstone Ventures, the life sciences-focused progeny of two VC stalwarts, has wrapped up a fund of its own, setting out with $172 million to back early-stage drug and med tech companies.
San Diego's Otonomy has hauled in another $49 million to advance its therapies for ear disorders, hoping to do for hearing-robbing ailments what VEGF inhibitors did for eye diseases.
After shifting its focus to immuno-oncology last year, Germany's Isarna Therapeutics has pulled down $7.6 million to jump-start the development of some preclinical cancer candidates.
Stalwart biotech investor Arch Venture Partners is putting together a $250 million 8th fund, according to a regulatory filing, piling on to the roughly $1.5 billion it currently manages.
A week after the FDA lifted a clinical hold on a trial of its lead cancer candidate, startup Juno Therapeutics has closed its overstuffed $176 million Series A, drawing cash from Arch Venture Partners, Amazon founder Jeff Bezos and others.
Kala Pharmaceuticals, co-founded by MIT biotech luminary Robert Langer, has closed a $22.5 million B round, cash the company says will help advance its novel approach to eye treatments.
A Detroit-based biotech has landed a $59.5 million round to continue its work on a nucleic acid-based DNAi cancer therapy now in a mid-stage trial. ProNAi Therapeutics CEO Mina Sooch says that's enough cash to get the company through 2016, with plans to pursue partnership talks as well as a discussion with the FDA about potential ways to accelerate the approval process for their lead therapy.
Venture investing in the biotech sector hit the $1.1 billion mark in the first quarter of the year--a surprisingly strong showing for what has generally been a quiet season in the U.S. industry.